Validating Stat3 in cancer therapy

This publication has 14 references indexed in Scilit:

• Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
  Nature Medicine, 2005
• A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
  Proceedings of the National Academy of Sciences, 2005
• Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells
  Oncogene, 2005
• In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy
  Oncogene, 2004
• The STATs of cancer — new molecular targets come of age
  Nature Reviews Cancer, 2004
• SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
  Proceedings of the National Academy of Sciences, 2003
• Transcription factors as targets for cancer therapy
  Nature Reviews Cancer, 2002
• STATs: transcriptional control and biological impact
  Nature Reviews Molecular Cell Biology, 2002
• Stat3 as an Oncogene
  Published by Elsevier ,1999
• Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
  Science, 1994